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Presence and Distress of Chemotherapy-Induced
Peripheral Neuropathy Symptoms in Upper Extremities
of Younger and Older Breast Cancer Survivors
Susan Storey, PhD, RN,1 Andrea Cohee, PhD, RN,1 Diane Von Ah, PhD, RN,1 Eric Vachon, PhD,
RN,1 Noah R. Zanville, PhD, RN,2 Patrick O. Monahan, PhD,3,4 Timothy E. Stump, MA,3 Victoria L.
Champion, PhD, RN1
Indiana University School of Nursing, Indianapolis, IN; 2Miami Cancer Institute, Baptist Health South Florida,
Miami, FL; 3Indiana University School of Medicine, Indianapolis, IN; 4Richard M. Fairbanks School of Public Health,
Indianapolis, IN
1

Purpose	The purposes of this study were to determine whether the presence of upper extremity chemotherapyinduced peripheral neuropathy (CIPN) symptoms (burning, pins/needles, numbness, pain, and skin
crawls) among breast cancer survivors (BCS) varied according to age (≤45 years or 55–70 years) and
to examine age group differences in upper extremity CIPN symptom distress.
Methods	The study was a secondary analysis of younger (n=505) and older (n=622) BCS. Inclusion criteria
were age of ≤45 years or 55–70 years; patient at 3–8 years postdiagnosis; patient received the
chemotherapy regimen of paclitaxel, doxorubicin, and cyclophosphamide; and patient did not have
recurrence. The Symptom Survivor Checklist was used to assess presence and distress of upper
extremity CIPN symptoms. Analyses explored whether age group predicted CIPN symptom presence
and distress while controlling for sociodemographic and medical variables.
Results 	Older BCS reported fewer pins/needles, numbness, and pain symptoms (odds ratios: 0.623–0.751).
Heart disease (odds ratios: 1.59–1.70) and progesterone-negative breast cancer (odds ratio: 0.663)
were significantly associated with one or more CIPN symptoms. Symptom distress ratings did not
differ by age groups; both age groups indicated distress from CIPN symptoms, with 25% or more
reporting distress as “moderately” or “quite a bit.”
Conclusions	Younger BCS reported more upper extremity CIPN symptoms. BCS in both groups continued to report
bothersome CIPN symptoms years after treatment. Study findings will assist clinicians in identifying
BCS at higher risk for upper extremity CIPN as well as inform development of appropriate tailored
interventions to mitigate these symptoms and facilitate restoration to age-related baseline function,
thereby improving quality of life for BCS. (J Patient Cent Res Rev. 2020;7:295-303.)
Keywords	
breast cancer; survivorship; chemotherapy-induced peripheral neuropathy; upper extremity; symptom
bother; symptom distress

C

hemotherapy-induced peripheral neuropathy
(CIPN) is one of the most prevalent, persistent,
and disruptive symptoms associated with common
antineoplastic treatments (eg, taxanes) for breast cancer.1-5
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Approximately two-thirds of breast cancer survivors
(BCS) report symptoms of CIPN during cancer treatment,6
with as many as 42% reporting lingering symptoms for up
to 3 years posttreatment.2,7-10 Symptoms of CIPN include
sensations of burning, pins/needles, numbness,1,5,9 pain,1,5
and/or skin crawls affecting the hands and/or feet.1,4,5,11-13
Although treatments have improved, the continued
reliance on taxanes (eg, paclitaxel) and other neurotoxic
agents to treat breast cancer has contributed to serious
and, at times, permanent changes that significantly
interfere with survivors’ daily functioning.5,7,9,11,12
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The onset of CIPN in BCS has been associated with
sociodemographic (age7,11,14,15 race,2,9,15 income,16
education,16 and alcohol consumption16) and medical
characteristics (comorbidities,5,11,16 hormone status,2
tumor size,10 body mass index,2,9,15 number of positive
nodes,10 and years from diagnosis17,18). Age in particular
may be an important risk factor in both CIPN symptom
presence and distress.7,11,14,15 While several studies have
found a higher prevalence and longer duration of CIPN
symptoms in older BCS (≥60 years of age),2,7,11,14-16 others
have found a higher prevalence of CIPN symptoms
in younger BCS.2,19 Further still, some studies found
no association between age and the presence of CIPN
symptoms.20,21 Most of these studies have concentrated
exclusively on the lower extremities, with little focus on
upper extremity CIPN symptoms.
Determining the impact of upper extremity CIPN
symptoms is important to study, as fine motor movements
can be impaired,22 potentially interfering with the ability of
BCS to perform daily activities. Understanding age-related
differences in the presence and impact of upper extremity
(shoulders, arms, hands, fingers) CIPN symptoms is
also important given that symptoms may differentially
affect independence and quality of life.5,17,19 While lower
extremity CIPN may be more distressing for older BCS
(eg, concerns about increased falls), upper extremity CIPN
may be more distressing for younger BCS (eg, concerns
about managing work and family responsibilities).
This study examined upper extremity CIPN symptoms
among BCS according to age group (younger vs older
BCS). Its aims were twofold. Aim 1 sought to determine
whether the presence of upper extremity CIPN symptoms
(burning, pins/needles, numbness, pain, and skin crawls)
varied according to age group. Aim 2 sought to examine age
group differences in level of distress from upper extremity
CIPN symptoms. This information would be particularly
useful for clinicians and researchers challenged in the
management of long-term and troubling CIPN symptoms.
Significant findings could assist with identifying BCS
at higher risk for CIPN and inform the development of
tailored interventions to mitigate these symptoms.

METHODS

Study Design and Sample

This study is a secondary analysis of 1127 BCS using
cohort data from an earlier cross-sectional quality-oflife study that included several self-reported measures
for common symptoms experienced by BCS. Details
of the parent study were described comprehensively
in a 2014 publication.23 Briefly, BCS were eligible if
they: 1) were 45 years old or younger (younger BCS) or
55–70 years old (older BCS) at diagnosis; 2) were 3–8

296 JPCRR • Volume 7, Issue 4 • Fall 2020

years postdiagnosis without recurrence; and 3) received
a chemotherapy regimen that included paclitaxel,
doxorubicin, and cyclophosphamide as part of their initial
breast cancer treatment. BCS who were 46–54 years of
age were excluded to avoid the potentially confounding
perimenopausal timeframe.
The secondary analysis presented hereafter was approved
by the coordinating university’s institutional review
board in 2019.
Measures

Sociodemographic Variables (Independent Variables):
Sociodemographic variables, including age, race, income,
education, and alcohol consumption, were self-reported.
Age was coded as a dichotomous variable of younger (≤45
years) or older (55–70 years), which was consistent with
the targeted enrollment groups as it is less common for BCS
over 70 years of age to receive this treatment regimen. Race
was coded as a categorical variable (white or nonwhite),
income was coded as a dichotomous variable (<$75,000
or ≥$75,000), and education was coded as a continuous
variable for years of education. Alcohol consumption
was queried by asking, “On those days that you drink
alcoholic beverages, about how many do you usually
have?” Response options were >5 drinks, 3–5 drinks, 1–2
drinks, and I do not drink (none). For this study, the alcohol
consumption variable was recoded into categories of ≥3
drinks per day, 1–2 drinks per day, or none.
Medical Variables (Independent Variables): Medical
information was collected via self-report from BCS and
included comorbidities (heart disease, hypertension,
diabetes), hormone status, tumor size, body mass index
(calculated from height and weight), number of positive
nodes, and years from diagnosis. Researchers reviewed
medical records to verify patient-reported information.
CIPN Symptoms (Dependent Variables): The Symptom
Survivor Checklist was developed for this study based
on review of CIPN literature.1,4,5,11-13 The checklist is a
12-item scale that assesses 5 common upper extremity
CIPN symptoms on the affected side, including burning,
pins/needles, numbness, pain, and skin crawls. BCS were
asked if the symptoms were present (yes/no). If present,
then BCS rated the extent to which they were bothered
or distressed by symptoms on a 5-point ordinal scale (0
= not at all; 1 = slightly; 2 = moderately; 3 = quite a bit;
4 = extremely). Higher scores were indicative of greater
symptom distress. Cronbach’s alpha for this scale in our
study was 0.78.
Data Analysis: Data analysis was conducted using SPSS
Statistics 25.0 (IBM Corp.), and significance was set at

Original Research

P<0.05. Two-tailed tests were used for all comparisons.
Prior to the analysis, Shapiro-Wilks tests were used to
test for normality of the data. Descriptive statistics were
used to summarize the distributions of sociodemographic
and medical variables. To examine age group differences
in sociodemographic and medical characteristics, we
used Pearson’s chi-squared tests for categorical variables
(race, income, marital status, comorbidities, hormone
status, alcohol consumption) and independent t-tests
for continuous variables (years of education, body mass
index, years from diagnosis, number of positive nodes,
tumor size).
For study aim 1, we first conducted 5 separate Pearson’s
chi-squared tests to determine if there was a significant
association between age group and the presence of each
of the 5 upper extremity CIPN symptoms: burning,
pins/needles, numbness, pain, and skin crawls. Three
significant symptoms were analyzed in a series of
separate binary logistic regression analyses to determine
whether age group was associated with the presence of
the symptoms while controlling for sociodemographic
(age, race, income, education, alcohol consumption) and
medical (heart disease, hypertension, diabetes, hormone
status, tumor size, body mass index, number of positive
nodes, years from diagnosis) variables that theoretically
could influence CIPN. In the regression model, each
symptom was entered as a dependent variable; age was an
independent variable along with other sociodemographic
and medical covariates. Using a backward deletion
approach, statistically nonsignificant sociodemographic
and medical characteristics were removed until the final
model was achieved.
For study aim 2, Mann-Whitney U tests were conducted
to examine age group differences in symptom distress.
Participants who did not report any CIPN symptoms
were removed from the Mann-Whitney U analysis.
If significant, backward deletion ordinal logistic
regression analyses would have been conducted to
determine if age group predicted symptom distress
while controlling for sociodemographic and medical
characteristics.

RESULTS

Sample Characteristics

Sociodemographic and medical characteristics of
younger (n=505) and older (n=622) BCS are shown in
Table 1. On average, BCS were 6 years posttreatment.
Compared to older BCS, younger BCS had significantly
higher incomes, were more likely to be married, had
fewer comorbidities, consumed more alcohol, and had
more years of education.
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Aim 1. Presence of CIPN Symptoms

Table 2 shows the chi-squared results for the presence
of upper extremity CIPN symptoms for the total sample
and by age group. Younger age group was significantly
associated with presence of 3 CIPN symptoms: pins/needles
(P=0.021), numbness (P<0.001), and pain (P<0.001).
Results of logistic regression analyses are summarized in
Table 3. Age significantly predicted the presence of pins/
needles, numbness, and pain symptoms. Older BCS had
lower odds of reporting upper extremity pins/needles,
numbness, and pain symptoms compared to younger
BCS (odds ratios: 0.623–0.751). Comorbid heart disease
also was a significant predictor of these 3 upper extremity
CIPN symptoms. BCS with heart disease were 1.59–1.70
times more likely to report pins/needles, numbness, and
pain symptoms. Additionally, hormone status predicted
the presence of the pins/needles symptom. Those with
positive progesterone receptor (PR) status had lower
odds (odds ratio: 0.663) of experiencing the pins/needles
symptom. While statistically significant, the variation
(R2) in the dependent variable based on our models
ranged from 2.3% to 2.9%, demonstrating a small but
consistent relationship between age and upper extremity
CIPN symptoms (pins/needles, numbness, pain).
Aim 2. Symptom Distress

Table 4 shows the level of distress associated with CIPN
symptoms by age group. Distress scores ranged from
1 (slightly) to 3 (quite a bit), with the typical score (ie,
median) indicating BCS were slightly or moderately
distressed. It should be noted that 2 or 3, depending on
the symptom, was not only the maximum score reported
but also the 75th percentile, indicating that 25% of BCS
perceived “moderately” or “quite a bit” of distress for each
symptom. Mann-Whitney U tests showed no significant
age group differences in upper extremity CIPN symptom
distress. Given that there were no statistically significant
age group differences in symptom distress scores, ordinal
logistic regression was not conducted.

DISCUSSION

The purpose of this study was to describe the presence
and distress level of upper extremity CIPN symptoms in
BCS 3 or more years posttreatment. The findings offer
several key insights. First, our results add to the literature
showing that younger BCS report the presence of upper
extremity CIPN symptoms more often than older BCS.
Second, comorbid heart disease and hormone status
were identified as risk factors for upper extremity CIPN
symptoms. Third, both younger and older BCS continued
to report upper extremity CIPN symptoms as distressing
several years posttreatment.
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Table 1. Comparison of Sociodemographic and Medical Characteristics of Younger (≤45 Years) and
Older (55–70 Years) Breast Cancer Survivors
Younger survivors,
n=505

Older survivors,
n=622

Race, n (%)
White
Non-White

459 (91)
46 (9)

582 (95)
30 (5)

0.114

Income, n (%)
<$75,000
≥$75,000

224 (45)
271 (55)

427 (72)
167 (28)

<0.001

Marital status, n (%)
Married
Non-Married
Missing

417 (83)
85 (17)
3 (0.6)

419 (69)
188 (31)
15 (2)

<0.001

Comorbidities, n (%)
Heart disease: Yes
Hypertension: Yes
Diabetes: Yes

36 (7)
74 (15)
28 (6)

83 (13)
328 (53)
93 (15)

<0.001
<0.001
<0.001

Positive hormone status, n (%)
Estrogen: Yes
Progesterone: Yes
HER2/neu: Yes

334 (67)
298 (62)
111 (27)

452 (75)
383 (65)
129 (25)

0.011
0.408
0.548

Alcohol consumption, n (%)
0 drinks
1–2 drinks
3 or more

144 (29)
294 (58)
67 (13)

251 (40)
347 (56)
24 (4)

<0.001

Years of education, mean (SD)

14.8 (2.6)

14.1 (2.7)

<0.001

Body mass index, mean (SD)

27.8 (6.1)

28.4 (5.9)

0.102

Years from diagnosis, mean (SD)

5.9 (1.5)

6 (1.5)

0.336

Number of positive nodes, mean (SD)

1.5 (2.6)

1.7 (3.2)

0.272

2 (1.4)

1.9 (1.3)

0.394

Variables

Tumor size in cm, mean (SD)

P

HER2, human epidermal growth factor receptor 2; SD, standard deviation.

Table 2. Presence of Peripheral Neuropathy Symptoms by Total Sample and Between Younger (≤45 Years) and
Older (55–70 Years) Breast Cancer Survivors
Symptom

All,
N=1127

Younger survivors,
n=505

Older survivors,
n=622

P*

Burning, n (%)

119 (9)

60 (12)

59 (10)

0.284

Pins/needles, n (%)

368 (33)

185 (37)

183 (30)

0.021

Numbness, n (%)

442 (39)

232 (46)

210 (34)

<0.001

Skin crawls, n (%)

109 (10)

58 (11)

51 (8)

0.085

Pain, n (%)

347 (31)

189 (37)

158 (25)

<0.001

*Determined by chi-squared test.
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Table 3. Predictors of Symptom Presence (Yes/No) Among BCS Based on Logistic Regression Analysis
Pins/needles [n=368; Χ2=4.92, df=4; R2=0.029; P<0.001]
Variable

Standard beta

SE beta

P

Odds ratio

95% CI

Older vs younger BCS
Heart disease: present vs not present

-0.286
0.457

0.144
0.224

0.048
0.041

0.751
1.59

0.566, 0.997
1.019, 2.451

PR hormone status: positive vs negative

-0.412

0.163

0.005

0.663

0.495, 0.886

Standard beta

SE beta

P

Odds ratio

95% CI

Older vs younger BCS

-0.449

0.137

0.001

0.638

0.488, 0.835

Heart disease: present vs not present

0.466

0.218

0.032

1.59

1.04, 2.44

Standard beta

SE beta

P

Odds ratio

95% CI

-0.474
0.551

0.145
0.223

0.001
0.013

0.623
1.70

0.469, 0.827
1.12, 2.68

Numbness [n=442; Χ2=5.056, df=4; R2=0.023, P=0.001]
Variable

Pain [n=347; Χ2=3.17, df=3; R2=0.025; P<0.001]
Variable
Older vs younger BCS
Heart disease: present vs not present

BCS, breast cancer survivors; df, degrees of freedom; PR, progesterone receptor; SE, standard error.

Table 4. Comparison of Symptom Distress by Age Groups
Score range,
potentiala (actual)

Younger survivors,
median (P25, P75)

Older survivors,
median (P25, P75)

Burning [n=290]

0–4 (1–3)

2.0 (1, 2)
n=120

2.0 (1, 3)
n=170

0.521

Pins/needles [n=347]

0–4 (1–2)

1.0 (1, 2)
n=173

1.0 (1, 2)
n=174

0.992

Numbness [n=376]

0–4 (1–3)

2.0 (1, 3)
n=193

2.0 (1, 2)
n=183

0.117

Pain [n=332]

0–4 (1–2)

1.0 (1, 2)
n=181

1.0 (1, 2)
n=151

0.330

Skin crawls [n=107]

0–4 (1–3)

2.0 (1, 2)
n=56

2.0 (1, 3)
n=51

0.885

Symptom

Pb

Survivors rated extent of distress on a 5-point scale: 0 = not at all; 1 = slightly; 2 = moderately; 3 = quite a bit; 4 = extremely).

a
b

Determined by Mann-Whitney U test.

P25, 25th percentile; P75, 75th percentile.

Aim 1. Presence of CIPN Symptoms

While factors such as treatment duration and the intensity
of taxane exposure that BCS receive during treatment
are known factors for developing chronic CIPN,10-12 the
role of age on these symptoms is less clear. In our study,
we found younger BCS were more likely to report upper
extremity CIPN symptoms of pins/needles, numbness,
and pain compared to their older counterparts. This
finding is consistent with other studies that have shown
younger BCS may be at higher risk of developing CIPN
symptoms.2,19 Ali and colleagues found younger BCS
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had a higher risk of CIPN than older BCS. However,
the researchers did not discuss how CIPN was defined
by location, limiting the ability to generalize the
finding to other BCS populations.2 Although underlying
mechanisms contributing to age-related differences in
CIPN symptoms are not clear, one possible explanation
is that, unlike younger BCS, older BCS may have
preexisting neuropathy and/or other neurodegenerative
loss from comorbid conditions that lessen their perception
of these symptoms.
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In contrast to our findings, other studies have shown that
older BCS are at increased risk for CIPN symptoms.
Hershman and colleagues linked clinical trial data with
Medicare claims and found older age to be the only
demographic factor associated with the presence of upper
and lower extremity CIPN symptoms.13 However, the
mean age of the sample (73 years) was older, which may
have influenced the study findings. Additionally, the lack
of access to baseline neurologic status — to determine if
symptoms of neuropathy were preexisting or new-onset
— may have resulted in higher reporting of symptom
presence.
Similarly, Lichtman and colleagues examined
neurotoxicity (neurosensory, neuromotor, neurocortical,
or neurocerebellar) symptoms among BCS (N=1048) in
3 age categories: <55 years, 55–64 years, and ≥65 years.24
Compared to those in the younger age categories, women
who were ≥65 years of age (n=272) reported earlier onset
and the presence of neurotoxicity with first- and secondline chemotherapy treatments.24 However, the focus of the
study was specific to neurotoxicity, which may influence
neuropathy but cannot be directly extrapolated to reflect
CIPN symptoms.
Other researchers have found no association between age
and CIPN symptoms. Schneider and colleagues studied
BCS (N=4554) in 3 age categories (≤45, 46–65, and >65
years) all receiving adjuvant taxane therapy.25 Although
they found CIPN symptoms in upper and lower extremities
were common complications of treatment, age was not
an associated factor.25 However, the researchers indicated
that a lack of uniform and validated CIPN assessments
may have decreased the reliability of the study findings.
More research is needed to assess if upper extremity
CIPN symptoms differ by age among BCS.
Although diabetes has been noted as a risk factor for
CIPN in BCS,13 we did not find diabetes to be associated
with upper extremity CIPN in our study. This finding may
be related to the typical presentation of CIPN symptoms
in the lower extremities in people with diabetes,26
whereas our study focused on upper extremity symptoms.
Additionally, the number of BCS with comorbid diabetes
(n=121) in our study was low.
An important finding from our study was that BCS
with comorbid heart disease were more likely to
report the presence of pins/needles, numbness, and
pain symptoms in the years following treatment. Heart
disease, hypertension, and diabetes, the most frequently
documented comorbidities in BCS,27-33 are all associated
with an increased risk of CIPN.6,30,31 The BCS in our study
received the same therapeutic regimen, which included
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two of the most common cardiotoxic chemotherapies
(doxorubicin and paclitaxel). Because we examined heart
disease broadly, we were not able to identify specific
cardiac pathologies nor determine if they occurred prior
to or after cancer diagnosis and treatment, limiting our
ability to determine if cardiovascular disease is a direct
risk factor for CIPN, especially in the upper extremities.
The influence of comorbid heart disease on CIPN
symptoms among BCS has not been well studied. As
BCS are living longer, the role of comorbid conditions on
CIPN symptoms is important to understand and warrants
further research. Clinicians should assess for the presence
of CIPN symptoms in BCS with a history of heart disease.
Finally, although estrogen receptor status did not
predict upper extremity CIPN symptoms, progesterone
status did. Specifically, BCS who were PR-positive
were less likely to report sensations of pins/needles in
the years following treatment than BCS who were PRnegative. Our findings are consistent with another study
that reported PR-negative status was associated with
an increased risk of developing CIPN.9 Studies have
suggested that progesterone may have neuroprotective
effects on the central and peripheral nervous systems by
promoting repair of myelin.33,34 Although, the degree to
which this may reduce the severity of taxane-induced
CIPN is unclear. More research is needed to understand
the role of hormone status on CIPN symptoms.
Aim 2. Symptom Distress

Results of our study found that, within an average of 6
years following treatment, BCS reported being distressed
by CIPN symptoms. Although younger BCS were more
likely than older BCS to report upper extremity CIPN
symptoms, we found no difference in distress levels
among younger and older BCS.
Studies examining differences by age of BCS on symptom
distress from upper extremity CIPN are lacking. We found
two studies that assessed CIPN symptom distress by age.
Tanabe and colleagues found CIPN symptoms were more
severe and persistent among older BCS (≥60 years of
age).14 However, the authors assessed CIPN symptoms
in combination of upper and lower extremities and did
not differentiate symptom distress by location. Wong and
colleagues assessed age-related differences in both upper
and lower extremity CIPN symptoms in cancer survivors
(n=425) and found younger survivors reported more
severe pain and more interference in activity from CIPN
symptoms when compared to older survivors.19 However,
the study included heterogenous cancer diagnoses as
well as survivors with metastatic disease, which may
have influenced the findings. Other studies have shown
younger survivors with CIPN report more difficulty with
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general activities, work, and other components of quality
of life,19,35,36 an important finding given that they have
not experienced nor adapted to the age-related losses that
commonly occur with aging.19
The lack of association between age and CIPN distress
observed in our study may have been a result of our
choice of measure, which only assessed upper extremity
CIPN symptoms. Future research should assess the
symptom experience of upper and lower CIPN symptoms
individually as well as collectively. Assessing upper and
lower extremity function separately in BCS may provide
helpful information as it relates to the differential impact
of CIPN on function and daily activities.
It is important to note, although we did not observe
an age-specific difference in the level of distress from
upper extremity CIPN symptoms, both younger and
older BCS still indicated distress from these symptoms
several years posttreatment, with 25% or more reporting
“moderately” or “quite a bit” of distress depending on the
particular symptom. This finding supports other research
that illustrates the lingering long-term impact of CIPN
symptoms experienced by BCS. Future research should
consider examining upper extremity CIPN symptoms
in younger and older BCS longitudinally across the
trajectory of cancer treatment into survivorship.
This study had several strengths and contributes to a
growing body of literature by identifying age-related
differences in 3 upper extremity CIPN symptoms. To our
knowledge, this is one of the first studies to evaluate the
impact of age and medical variables on specific upper
extremity CIPN symptoms in BCS and in a patient cohort
that is >3 years posttreatment. Results from our analysis
were drawn from a large nationally representative sample of
BCS who received one of the most common taxane-based
regimens (a primary driver of CIPN in BCS), increasing
the generalizability of findings. The study included a 10year separation between younger and older BCS, reducing
variation in the sample. Given our findings that younger
BCS are at risk for experiencing CIPN symptoms, future
research should explore the development and testing of
age-appropriate interventions to restore function, reduce
distress, and improve quality of life.
Limitations

Study findings also need to be considered in the context
of several limitations. First, because of its cross-sectional
design, neurological diagnostic testing was not available,
limiting the ability to identify baseline CIPN symptoms
or determine if the symptoms evolved over time. Second,
the upper age limit of older BCS in our study was 70
years, whereas other studies included much older subjects
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(ie, ≥65 years), which may have influenced these findings.
Third, we did not have access to information on cumulative
exposure to taxanes for participants, which could have
an impact on CIPN symptoms. Fourth, because African
American women, who have a 2- to 3-fold higher risk of
taxane-induced CIPN than Caucasian women,11,13 were
not well represented in this study, generalizability to all
race/ethnicities is limited. Finally, although the Survivor
Symptom Checklist demonstrated an acceptable Cronbach’s
alpha, additional validation of the tool is warranted. Despite
these limitations, this study’s findings add to the body of
knowledge as it relates to presence and distress of upper
extremity CIPN symptoms from the perspectives of
younger and older BCS, an understudied area.
Implications for Practice

The information from this study will be particularly useful
for clinicians and researchers challenged in the care of
long-term and troubling CIPN symptoms. We found
upper extremity CIPN symptoms can be distressing for
BCS years posttreatment. CIPN symptoms are typically
assessed in combination with lower extremity symptoms
at the onset and intermittently during active treatment
for cancer. Our findings elucidate the need for ongoing
assessment and monitoring of upper extremity CIPN
symptoms in BCS throughout the cancer trajectory, well
into survivorship. These assessments could facilitate
referrals to rehabilitative programs to implement agespecific rehabilitative interventions geared towards
maximizing safety and physical function, hopefully
improving overall quality of life for BCS.
Future research should consider examining upper
extremity CIPN symptoms longitudinally in a more
diverse sample of BCS across the trajectory of cancer
treatment and into survivorship. Additionally, research
testing age-appropriate tailored interventions toward
mitigating these symptoms in BCS may facilitate
restoration to age-related baseline functional status.

CONCLUSIONS

Findings from this study have integral implications for
occupational and rehabilitative staff when developing
treatment plans aimed toward improving safety
and functional performance for long-term BCS in
survivorship programs. Of particular importance is the
finding that younger BCS, for whom work is likely to be
a critical issue, are more likely than older BCS to report
pain, tingling, and numbness in their upper extremities.
Although research specific to upper extremity CIPN
symptoms in BCS is nominal, several studies have
implicated the presence, number, type, and duration
of CIPN symptoms (upper/lower combined) with
difficulty performing work-related tasks.36-38 Successful
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rehabilitation efforts would facilitate strategies to
increase participation in work, spur earlier return to
work, and improve activities of daily living and overall
quality of life.
Patient-Friendly Recap
•S
 urvivors of breast cancer may experience pain,
numbness, or other sensations in their extremities
years after treatment. These symptoms stem from
a nerve condition called chemotherapy-induced
peripheral neuropathy (CIPN).
• The authors studied if presence and degree of
distress from CIPN symptoms varied by age
between breast cancer survivors diagnosed at a
younger (≤45 years) or older (55–70 years) age.
• They found that upper extremity pain, pins/needles,
and numbness were more frequently reported by
younger survivors. They also significantly associated
heart disease and progesterone-negative breast
cancer with certain CIPN symptoms.
•B
 oth age groups largely indicated that CIPN
symptoms caused them a slight-to-moderate
degree of distress years after treatment.
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